Literature DB >> 6412949

Mechanism of antihypertensive action of ketanserin in man.

S G Ball, J R Zabludowski, J I Robertson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6412949      PMCID： PMC1549543          DOI： 10.1136/bmj.287.6398.1065

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  1 in total

1.  Is ketanserin a D receptor antagonist?

Authors: 
Journal:  Lancet       Date:  1983-03-26       Impact factor: 79.321
  1 in total
  9 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Response to tilting in hypertensive patients receiving ketanserin.

Authors:  L A Ferrara; F Pasanisi; M L Fasano; S Soro
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

3.  Comparative haemodynamic effects of ketanserin and ritanserin in the proximal and distal upper limb circulations of hypertensive patients.

Authors:  N P Chau; I Pithois-Merli; J Levenson; A C Simon
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

4.  Effect of the 5-hydroxytryptamine type 2 receptor antagonist, ketanserin, on blood pressure, the renin-angiotensin system and sympatho-adrenal function in patients with essential hypertension.

Authors:  J R Zabludowski; C Zoccali; C G Isles; G D Murray; J I Robertson; G C Inglis; R Fraser; S G Ball
Journal:  Br J Clin Pharmacol       Date:  1984-03       Impact factor: 4.335

5.  Ketanserin in essential hypertension: a double-blind, placebo-controlled study.

Authors:  H A Cameron; L E Ramsay
Journal:  Postgrad Med J       Date:  1985-07       Impact factor: 2.401

6.  Controlled trial of ketanserin in hypertension.

Authors:  J C McGourty; J H Silas; K J Cowen
Journal:  Br J Clin Pharmacol       Date:  1985-07       Impact factor: 4.335

7.  In vivo and in vitro activity of selective 5-hydroxytryptamine2 receptor antagonists.

Authors:  S Conolan; M J Quinn; D A Taylor
Journal:  Br J Pharmacol       Date:  1986-09       Impact factor: 8.739

8.  Effect of intravenous ketanserin on plasma catecholamines and renin activity in normal volunteers.

Authors:  I W Reimann; D Ratge; H Wisser; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Antihypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rat.

Authors:  A Pettersson; K Gradin; T Hedner; B Persson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.